Mobility Bio and Image Analysis Group Partner to Objectively Assess Osteoarthritis Patient Response in a Proof of Concept Study using AI-Driven Imaging Biomarkers
Mobility Bio and Image Analysis Group Partner to Objectively Assess Osteoarthritis Patient Response in a Proof of Concept Study using AI-Driven Imaging Biomarkers
Mobility Bio, an emerging bio-pharma focused on the development of novel therapies for joint diseases and IAG, Image Analysis Group, a strategic bio-pharma imaging expert announce a partnership in the development of Mobility’s lead asset.
The IAG team has significant experience in using medical imaging to support drug development. IAG will use their proprietary AI-driven methodology for Dynamic Enhanced MRI Quantification (DEMRIQ) to acquire and analyse MRI images in Mobility Bio’s first in human clinical study of their novel therapeutic.
‘We are pleased to partner with Mobility and bring world-class imaging experts, who bring their expertise to maximise success in the clinic and help finding a solution for OA patients.’ said Dr. Olga Kubassova, IAG’s CEO.
‘We are delighted to work with IAG and leverage their advanced imaging capabilities as we study the potential of our lead product to benefit patients with osteoarthritis’ said Dr Tharak Rao, Mobility Bio’s Chief Medical Officer.
About Image Analysis Group (IAG):
IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com
About Mobility Bio:
Founded by Stanford physicians and scientists, Mobility is advancing treatments for osteoarthritis and other diseases that cause joint pain and disability. Osteoarthritis affects over 20 million people in the United States alone and lacks effective treatments to slow the progression of disease. Mobility’s new OA medicines are designed to reduce pain and discomfort, alleviate the underlying processes that lead to joint damage, and improve patients’ quality of life.
For more information, please reach out to: imaging.experts@ia-grp.com